For nearly two decades, DeMonica Amerson believed she was battling multiple sclerosis. Daily injections, mounting fatigue, and even a surgical port in her chest became part of her life after doctors diagnosed her in 2001 when telltale symptoms pointed toward the chronic nerve disease. But in 2019—amid a surge in severe symptoms—routine treatment took a dramatic turn when specialized bloodwork finally uncovered the real diagnosis: neuromyelitis optica spectrum disorder (NMOSD), a rarer autoimmune disease that closely mimics MS but demands different treatment and management.

Amerson’s initial diagnosis, triggered by optic neuritis and signs reminiscent of lupus, led to years of MS-targeted therapies. She became a prominent advocate for the MS National Foundation, sharing her story and raising awareness. Yet, the full story remained hidden beneath the surface. Only after an alarming incident of lethargy and numbness forced a hospital visit did medical staff pursue additional, more targeted tests. The revelation left Amerson shocked and angry, thrusting her into a new cycle of treatment and advocacy. In her own words to CBS News, she was “so mad that [she] walked out” of her doctor’s office after hearing about the diagnostic error.

This kind of misdiagnosis is not as rare as some may hope. Studies cited by both CBS News and PolitiFact indicate that as many as 15% to 20% of MS cases in the United States are incorrect—often due to the subtle overlap of symptoms among autoimmune disorders, including lupus, sarcoidosis, and less frequently recognized conditions like NMOSD. The two diseases attack similar parts of the central nervous system, producing symptoms such as vision loss, muscle weakness, and fatigue. Yet, the specific proteins driving NMOSD can only be reliably detected via specialized testing, something Amerson did not receive until almost 20 years after her original diagnosis.

Since learning the truth, Amerson has switched to Uplizna—an infusion medication tailored to NMOSD—reporting significant improvements and a new sense of hope. She describes managing her condition “day by day” and remains vocal about her experience, campaigning now for NMOSD awareness in addition to her past MS efforts. Her case, although deeply personal, stands as a public lesson about the pitfalls of misdiagnosis and the critical importance of thorough, up-to-date testing for complex autoimmune conditions.

The circumstances that led to Amerson’s original misdiagnosis remain unclear, but they illustrate the wider diagnostic challenges clinicians face. Advocates for affected patients now argue for routine, specialized screening for those with ambiguous or evolving central nervous system symptoms—especially as new therapies and biomarker tests become available. For patients like Amerson, the consequences of an error can echo for years, underscoring the need for vigilance in diagnosis, treatment, and research.